Document Detail


Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy.
MedLine Citation:
PMID:  22196919     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
In recent years there has been undoubted progress in the evaluation and development of targeted agents for non-small cell lung cancer (NSCLC). A major contributor has been the discovery of molecular subtypes harbouring a critical oncogenic driver mutation, specifically sensitizing mutations in the epidermal growth factor receptor (EGFR) gene and the EML4-ALK gene translocation. Radiotherapy is a cornerstone of therapy for the curative intent treatment of early stage, localized disease; and for the palliation of symptoms in advanced, metastatic disease. In this molecular targeted era there is limited understanding of how best to combine targeted agents with radiotherapy and in general clinical studies with radiotherapy have lagged behind studies of targeted agents with chemotherapy. Here we summarise the progress made to date and highlight future directions.
Authors:
Pek Keng Koh; Corinne Faivre-Finn; Fiona H Blackhall; Dirk De Ruysscher
Related Documents :
25081339 - Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 ...
9288509 - Is there a role for video-assisted thoracoscopy in the staging of non-small cell lung c...
21865399 - "pulsatile" high-dose weekly erlotinib for cns metastases from egfr mutant non-small ce...
21996089 - Suv(max) during 18fdg-pet scanning in small cell lung cancer: similar information as in...
18024539 - Problems in the current diagnostic standards of clinical n1 non-small cell lung cancer.
24669009 - Development and external validation of a nomogram for overall survival after curative r...
1958389 - Hodgkin's disease in northern sweden 1971-1981. iii. the clinical and prognostic impact...
8142149 - Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (lak...
16224399 - Rationale for maintenance or consolidation therapy in ovarian cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-22
Journal Detail:
Title:  Cancer treatment reviews     Volume:  -     ISSN:  1532-1967     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7502030     Medline TA:  Cancer Treat Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier Ltd.
Affiliation:
Department of Clinical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of a change of computer software on prescription drug errors in an emergency department.
Next Document:  Forest carbon stocks and fluxes in physiographic zones of India.